Eagle Pharmaceuticals Inc (NASDAQ:EGRX) — Market Cap & Net Worth
Market Cap & Net Worth: Eagle Pharmaceuticals Inc (EGRX)
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has a market capitalization of $3.29 Million ($3.29 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29411 globally and #6004 in its home market, demonstrating a 71.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eagle Pharmaceuticals Inc's stock price $1.29 by its total outstanding shares 13157553 (13.16 Million). Also see EGRX current and non-current assets for a full breakdown of the balance sheet.
Eagle Pharmaceuticals Inc Market Cap History: 2025 to 2026
Eagle Pharmaceuticals Inc's market capitalization history from 2025 to 2026. Data shows growth from $4.47 Million to $16.91 Million (0.00% CAGR). Also see cash efficiency ratio of Eagle Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Eagle Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eagle Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check EGRX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EGRX by Market Capitalization
Companies near Eagle Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review Eagle Pharmaceuticals Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Eagle Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Eagle Pharmaceuticals Inc Historical Marketcap From 2025 to 2026
Between 2025 and today, Eagle Pharmaceuticals Inc's market cap moved from $4.47 Million to $ 16.91 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.91 Million | +277.94% |
| 2025 | $4.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Eagle Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.29 Million USD |
| MoneyControl | $3.29 Million USD |
| MarketWatch | $3.29 Million USD |
| marketcap.company | $3.29 Million USD |
| Reuters | $3.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more